Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Gelesis Holdings, Inc. (GLS)

0.48   0.135 (39.29%) 12-02 16:01
Open: 0.3658 Pre. Close: 0.3446
High: 0.48 Low: 0.3283
Volume: 203,067 Market Cap: 35(M)

Technical analysis

as of: 2022-12-02 4:23:12 PM
Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.64     One year: 0.75
Support: Support1: 0.35    Support2: 0.23
Resistance: Resistance1: 0.55    Resistance2: 0.64
Pivot: 0.39
Moving Average: MA(5): 0.37     MA(20): 0.36
MA(100): 0.96     MA(250): 3.32
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 41.5     %D(3): 40.5
RSI: RSI(14): 47.5
52-week: High: 12.22  Low: 0.23
Average Vol(K): 3-Month: 154 (K)  10-Days: 115 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GLS ] has closed below upper band by 36.5%. Bollinger Bands are 54.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.48 - 0.49 0.49 - 0.49
Low: 0.32 - 0.32 0.32 - 0.33
Close: 0.41 - 0.42 0.42 - 0.43

Company Description

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Headline News

Wed, 30 Nov 2022
2022 Mercedes-Benz GLB First Drive Review: Scaled-down GLS for GLC money? - Zee News

Wed, 30 Nov 2022
Mercedes GLB three-row SUV is your 'affordable' alternative to GLS - HT Auto

Tue, 29 Nov 2022
GLS-backed student team to develop in-air cargo drone charging system - Cargo Facts

Tue, 29 Nov 2022
Mansory Thinks the Maybach GLS Deserves a Bulbar and a New Photo Shoot, What Say You? - autoevolution

Mon, 28 Nov 2022
Late, Post-COVID Cardiac Dysfunction Linked to Preexisting CAD - Medscape

Mon, 28 Nov 2022
Suryakumar Yadav gives spa to his Mercedes Benz GLS SUV: SKY's car collection, net worth - DNA India

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 20 (M)
% Held by Insiders 52.5 (%)
% Held by Institutions 34.1 (%)
Shares Short 867 (K)
Shares Short P.Month 558 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -562
Return on Assets (ttm) -56.6
Return on Equity (ttm) -234.7
Qtrly Rev. Growth 312
Gross Profit (p.s.) 0.01
Sales Per Share 0.21
EBITDA (p.s.) -1.48
Qtrly Earnings Growth 0
Operating Cash Flow -60 (M)
Levered Free Cash Flow -35 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 1.95
Price to Cash Flow -0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.